The Oley Foundation
The Oley Foundation is a national non-profit organization, founded in 1983. They aim to “enrich the lives of patients dependent on home intravenous nutrition (parenteral) and tube feeding (enteral) through education, advocacy, and networking.” They are a “resource for consumer’s families, clinicians and industry representatives, and other interested parties. The Foundation gives members the tools and confidence they need to manage their complex therapy and enables them to achieve normalcy in their lives.”
Condition Awareness & Advocacy
Here is a list of conditions this partner raises awareness and advocacy for:
Resources & Support
Patient Worthy Posts on Gastroschisis, Short bowel syndrome, Systemic Scleroderma, Gastroparesis
Crohn’s Disease: New Predictive Marker for Complications After Surgery
In a study published on Hindawi, a team of scientists have discovered that the C-reactive protein to albumin (CAR) ratio can be used to predict
New Research Program Begins for Oral GLP-2 for SBS
In the past, patients with short bowel syndrome (SBS) were treated with teduglutide, a daily injection. However, injections can be painful, difficult to administer,
July 30th is Gastroschisis Awareness Day: Spreading Rare Disease Awareness
July 30th, 2020 is recognized as Gastroschisis Awareness Day. This event aims to help spread awareness about gastroschisis, a rare birth defect, among both the
Celebrate Gastroschisis Awareness Month with Avery’s Angels Foundation
July is Gastroschisis Awareness Month! Thanks to the great work of the Avery’s Angels Gastroschisis Foundation, there are a number of ways and resources to
The FDA Has Just Approved Teduglutide for Children with Short Bowel Syndrome
Short Bowel Syndrome Short bowel syndrome (SBS) is a rare condition which occurs when patients have a large portion of their intestine removed. The surgery
Data From Early Short Bowel Syndrome Trials Presented
According to a story from PR Newswire, the biopharmaceutical company Therachon AG recently issued a presentation of results from the company’s Phase I clinical trial.
